

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging

Karen B. Onel,¹ Daniel B. Horton,² Daniel J. Lovell,³ Susan Shenoi,⁴ Carlos A. Cuello,⁵ Sheila T. Angeles-Han,³ Mara L. Becker,⁶ Randy Q. Cron,⁷ Brian M. Feldman,⁸ Polly J. Ferguson,⁹ Harry Gewanter,¹⁰ Jaime Guzman,¹¹ Yukiko Kimura,¹² Tzielan Lee,¹³ Katherine Murphy,¹⁴ Peter A. Nigrovic,¹⁵ Michael J. Ombrello,¹⁶ C. Eglar Rabinovich,⁶ Melissa Teshler,¹⁷ Marinka Twilt,¹⁸ Marisa Klein-Gitelman,¹⁹ Fatima Barbar-Smiley,²⁰ Ashley M. Cooper,²¹ Barbara Edelheit,²² Miriah Gillispie-Taylor,²³ Kimberly Hays,²⁴ Melissa L. Mannion,⁷ Rosemary Peterson,²⁵ Elaine Flanagan,²⁶ Nadine Saad,²⁷ Nancy Sullivan,²⁸ Ann Marie Szymanski,²⁹ Rebecca Trachtman,³⁰ Marat Turgunbaev,³¹ Keila Veiga,³² Amy S. Turner,³¹ and James T. Reston²⁸

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions, and drug formularies or other third-party analyses that cite ACR guidelines should state this. These recommendations cannot adequately convey all uncertainties and nuances of patient care.

The ACR is an independent, professional, medical and scientific society that does not guarantee, warrant, or endorse any commercial product or service.

Objective. To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.

Methods. We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.

Results. Recommendations in this guideline include the use of physical therapy and occupational therapy interventions; a healthy, well-balanced, age-appropriate diet; specific laboratory monitoring for medications; widespread use of immunizations; and shared decision-making with patients/caregivers. Disease management for all patients with JIA is addressed with respect to nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.

Conclusion. This clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis, and a concurrent 2021 guideline

on oligoarthritis, temporomandibular arthritis, and systemic JIA. It serves as a tool to support clinicians, patients, and caregivers in decision-making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision-making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.

INTRODUCTION

Reflecting the changing medical landscape, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines and plans to review these annually and update as needed. The process for updating the 2011 and 2013 juvenile idiopathic arthritis (JIA) guidelines (1,2) began in 2017. Important clinical topics for consideration were first identified at a meeting to define the scope of the guidelines. Advances in the treatment of JIA and better understanding of pathogenesis dictated separating this clinical practice guideline into several parts due to the breadth of topics. The first part, addressing polyarthritis, sacroiliitis, enthesitis, and uveitis, was published in 2 articles in 2019 (3,4). The second part, presented here in 2 articles, covers 1) oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA, and 2) nonpharmacologic treatments, patient monitoring, immunizations, and imaging (5). The methods and literature review described below reflect the unified process used for the second part of these guidelines, including both articles.

We developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, recommendations were then developed based on the best available evidence for commonly encountered clinical scenarios. Prior to final voting, input was

sought from relevant stakeholders including a panel of young adults with JIA and caregivers of children with JIA to consider their values and perspectives in making recommendations. Both the patient/caregiver and guideline Voting Panels stressed the need for individualized treatment while being mindful of available evidence and the need to include recommendations on nonpharmacologic therapies.

METHODS

This guideline followed the ACR guideline development process and ACR policy guiding management of conflicts of interest and disclosures (<https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines>), which include GRADE methodology (6,7), and adheres to Appraisal of Guidelines, Research and Evaluation criteria (8). Supplementary Appendix 1 (available on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>) includes a detailed description of the methods. Briefly, the Core Leadership Team (KBO, DBH, DJL, SS) drafted clinical PICO questions. PICO questions were revised and finalized based on feedback from the entire guideline development group and the public. The Literature Review Team performed systematic literature reviews for each PICO (for search terms, see Supplementary Appendix 2,

This article is published simultaneously in *Arthritis Care & Research*.

Supported by the American College of Rheumatology. Dr. Horton's work was supported by funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (award K23-AR-070286). Dr. Ombrello's work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (award AR-041198).

¹Karen B. Onel, MD: Hospital for Special Surgery, New York, New York; ²Daniel B. Horton, MD, MSCE: Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey; ³Daniel J. Lovell, MD, MPH, Sheila T. Angeles-Han, MD, MSc: Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio; ⁴Susan Shenoi, MBBBS, MS, RhMSUS: Seattle Children's Hospital and Research Center and University of Washington, Seattle; ⁵Carlos A. Cuello, MD, PhD: McMaster University, Hamilton, Ontario, Canada; ⁶Mara L. Becker, MD, MSCE, C. Eglia Rabinovich, MD, MPH: Duke University, Durham, North Carolina; ⁷Randy Q. Cron, MD, PhD, Melissa L. Mannion, MD, MSPH: University of Alabama at Birmingham; ⁸Brian M. Feldman, MD, MSc: The Hospital for Sick Children, Toronto, Ontario, Canada; ⁹Polly J. Ferguson, MD: University of Iowa Carver College of Medicine, Iowa City; ¹⁰Harry Gewanter, MD: Children's Hospital of Richmond at VCU, Richmond, Virginia; ¹¹Jaime Guzman, MD, MSc: BC Children's Hospital, Vancouver, British Columbia, Canada; ¹²Yukiko Kimura, MD: Hackensack Meridian School of Medicine, Hackensack, New Jersey; ¹³Tzielan Lee, MD: Stanford University, Palo Alto, California; ¹⁴Katherine Murphy, MPH: Louisiana Department of Health, New Orleans; ¹⁵Peter A. Nigrovic, MD: Boston Children's Hospital and Brigham and Women's Hospital, Boston, Massachusetts; ¹⁶Michael J. Ombrello, MD: NIH, Bethesda, Maryland;

¹⁷Melissa Teshler, MD: University of Chicago, Chicago, Illinois; ¹⁸Marinka Twilt, MD, MSCE, PhD: University of Calgary and Alberta Children's Hospital, Calgary, Alberta, Canada; ¹⁹Marisa Klein-Gitelman, MD, MPH: Ann & Robert Lurie Children's Hospital of Chicago and Northwestern University, Chicago, Illinois; ²⁰Fatima Barbar-Smiley, MD, MPH: Nationwide Children's Hospital, Columbus, Ohio; ²¹Ashley M. Cooper, MD: Children's Mercy Hospital, Kansas City, Missouri; ²²Barbara Edelheit, MD: Connecticut Children's Medical Center, Hartford; ²³Miriam Gillispie-Taylor, MD: Baylor College of Medicine, Houston, Texas; ²⁴Kimberly Hays, MD: Penn State Health Children's Hospital, Hershey, Pennsylvania; ²⁵Rosemary Peterson, MD, MSCE: Dell Children's Medical Center, Austin, Texas; ²⁶Elaine Flanagan, MD: Emory University, Atlanta, Georgia; ²⁷Nadine Saad, MD: University of Michigan, Ann Arbor; ²⁸Nancy Sullivan, BA, James T. Reston, PhD, MPH: ECRI Institute, Plymouth Meeting, Pennsylvania; ²⁹Ann Marie Szymanski, MD: Johns Hopkins All Children's Hospital, St. Petersburg, Florida; ³⁰Rebecca Trachtman, MD: Icahn School of Medicine at Mount Sinai, New York, New York; ³¹Marat Turgunbaev, MD, MPH, Amy S. Turner: American College of Rheumatology, Atlanta, Georgia; ³²Keila Veiga, MD: Maria Fareri Children's Hospital, Valhalla, New York.

Author disclosures are available at <https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42036&file=art42036-sup-0001-Disclosureform.pdf>.

Address correspondence to Karen B. Onel, MD, Hospital for Special Surgery, 535 East Seventieth Street, Fifth Floor, New York, NY 10021. E-mail: onelk@hss.edu.

Submitted for publication March 4, 2021; accepted in revised form November 23, 2021.

<https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>), graded the quality of evidence (high, moderate, low, or very low), and produced the evidence report (Supplementary Appendix 3, <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>). It should be noted that GRADE methodology does not distinguish between lack of evidence (i.e., none) and very low-quality evidence. The Core Team defined multiple critical study outcome(s) for PICO relevant to each JIA phenotype (Supplementary Appendix 4, <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>).

A panel of 15 members, including young adults with JIA and caregivers of children with JIA, met virtually (moderated by the principal investigator [KBO]), reviewed the evidence report, and provided input to the Voting Panel. Two members of this panel were also members of the Voting Panel to ensure that the patient voice was part of the entire process. The Voting Panel reviewed the evidence report and patient/caregiver perspectives and then discussed and voted on recommendation statements. Consensus required $\geq 70\%$ agreement on both direction (for or against) and strength (strong or conditional) of each recommendation, as per ACR practice. A recommendation could be either in favor of or against the proposed intervention and either strong or conditional. According to GRADE, a recommendation is categorized as strong if the panel is very confident that the benefits of an intervention clearly outweigh the harms (or vice versa); a conditional recommendation denotes uncertainty regarding the balance of benefits and

harms, such as when the evidence quality is low or very low, or when the decision is sensitive to individual patient preferences, or when costs are expected to impact the decision. Thus, conditional recommendations refer to decisions in which incorporation of patient preferences is a particularly essential element of decision-making. Examples of each class of intervention addressed in the recommendations are shown in Table 1. Rosters of the Core Leadership Team, Literature Review Team, and both panels are included in Supplementary Appendix 5 (<https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>).

Guiding principles

The development of the recommendations presented herein was guided by the following principles:

1. Consistent with the ACR's 2019 JIA guidelines, these recommendations are for persons already diagnosed as having JIA.
2. Coexisting extraarticular conditions that would influence disease management and monitoring, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines.
3. Recommendations for immunizations were evaluated to be consistent with guidelines from the American Academy of Pediatrics (AAP) and the Advisory Committee on Immunization Practices (ACIP) while taking into consideration the unique needs of persons with JIA.
4. Recommendations are intended to be used by all clinicians caring for persons with JIA.
5. Shared decision-making with families and patients is critical.

Table 1. Classes of interventions

Nonsteroidal antiinflammatory drugs	Any at therapeutic dosing (ibuprofen, naproxen, tolmetin, indomethacin, meloxicam, nabumetone, diclofenac, piroxicam, etodolac, celecoxib)
Conventional synthetic disease-modifying antirheumatic drugs	Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, calcineurin inhibitors (cyclosporin A, tacrolimus)
Biologic disease-modifying antirheumatic drugs	Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol); other biologic response modifiers (abatacept, tocilizumab, anakinra, canakinumab)
Targeted synthetic disease-modifying antirheumatic drugs	JAK inhibitor (tofacitinib)
Glucocorticoids	Oral (any); intravenous (any); intraarticular (triamcinolone acetonide, triamcinolone hexacetonide)
Immunizations	Live attenuated; inactivated
Nonpharmacologic therapies	Physical therapy; occupational therapy; dietary changes; herbal supplements

RESULTS/RECOMMENDATIONS

The initial literature review (through August 7, 2019) identified 4,308 articles in searches for all PICO questions pertaining to oligoarthritis, TMJ arthritis, systemic JIA, and the topics addressed in this report, including nonpharmacologic therapies, nutrition, supplements, medication monitoring, immunizations, and imaging. A July 9, 2020 search update identified 367 more references, for a total of 4,675 articles after duplicates and non-English publications were removed. After exclusion of 2,291 titles and abstracts, 2,384 full-text articles were screened. Of these, 1,939 were excluded (Supplementary Appendix 6, on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>), leaving 445 articles to be considered for the evidence report. Ultimately, 336 articles were matched to PICO questions and included in the final evidence report. Quality of evidence was uniformly low or very low; 17 PICO questions lacked any associated evidence and, as per GRADE methodology, were categorized as very low (Tables 2–6). The recommendations that follow are based on 62 PICO questions. Several PICO questions were split into 24 sub-PICO questions to

Table 2. Strength of recommendations and quality of supporting evidence

Topic	Strength of recommendation			Quality of supporting evidence			
	No. of recommendations	Conditional	Strong	Very low	Low	Moderate	High
Nonpharmacologic therapies	4	2	2	4	0	0	0
Medication monitoring*	20	17	3	17	0	0	0
Infection surveillance/immunizations	7	3	4	5	2	0	0
Imaging	2	1	1	2	0	0	0
Total	33	23	10	28	2	0	0

* Lack of evidence for tofacitinib given the US Food and Drug Administration approval date.

improve specificity. Nine questions initially posed were discarded by the Voting Panel because of redundancy or lack of relevance. Final recommendations are described below and in Tables 3–6, which include reference(s) to which PICO question(s) in the evidence report correspond to the recommendation statement.

Nonpharmacologic therapies (Table 3)

Patient/caregiver panelists specifically asked that recommendations for nonpharmacologic treatment be included in this guideline, although they understood that evidence to support specific statements is generally lacking.

Physical and occupational therapy (PT/OT)

PT and OT are conditionally recommended regardless of concomitant pharmacologic therapy.

Reasons for using PT or OT include maintaining or improving joint range of motion (particularly for contractures), improving strength, reversing functional deficits, improving endurance, preventing injury, and promoting improved participation in activities of daily living, family routines, and occupations (9,10).

Nutrition

A discussion of healthy, age-appropriate diet is strongly recommended.

Use of a specific diet to treat JIA is strongly recommended *against*.

Ample evidence supports the value of a healthy, balanced, nutrient-dense diet for all children, with consideration of specific age-appropriate nutritional requirements (e.g., fat, calcium)

Table 3. Nonpharmacologic therapies*

Recommendation	Certainty of evidence	PICO evidence report(s) basis	Page no(s). of evidence tables†
A discussion of healthy, age-appropriate diet is strongly recommended.	Very low	PICO 7. In children with oligoarticular JIA, should dietary or herbal interventions be recommended, in addition to whatever other therapeutic options are given, versus not recommending them?	48–49
Use of a specific diet to treat JIA is strongly recommended <i>against</i> .	Very low	PICO 7. In children with oligoarticular JIA, should dietary or herbal interventions be recommended, in addition to whatever other therapeutic options are given, versus not recommending them?	48–49
Use of supplemental or herbal interventions specifically to treat JIA is conditionally recommended <i>against</i> .	Very low	PICO 17. In children with JIA with active TMJ arthritis, should dietary or herbal interventions be recommended, in addition to whatever other therapeutic options are given, versus not recommending them?	60
Physical and occupational therapy are conditionally recommended regardless of concomitant pharmacologic therapy.	Very low	PICO 8. In children with oligoarticular JIA, regardless of disease activity and poor prognostic features, should PT/OT versus no PT/OT (regardless of concomitant medical therapy) be recommended? PICO 18. In children with JIA with active TMJ arthritis, regardless of disease activity and poor prognostic features, should PT versus no PT (regardless of concomitant medical therapy) be recommended?	49–51 60

* PICO = Patient/Population, Intervention, Comparison, and Outcomes; JIA = juvenile idiopathic arthritis; TMJ = temporomandibular joint; PT = physical therapy; OT = occupational therapy.

† In Supplementary Appendix 3, on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>.

Table 4. Medication monitoring*

Recommendation	Certainty of evidence	PICO evidence report(s) basis	Page no(s). of evidence tables†
NSAIDs: Monitoring via CBC counts, LFTs, and renal function tests every 6–12 months is conditionally recommended.	Very low	PICO 30. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel, and urinalysis) for children receiving long-term daily NSAID treatment?	144–145
MTX: Monitoring via CBC counts, LFTs, and renal function tests within the first 1–2 months of usage and every 3–4 months thereafter is strongly recommended.	Very low	PICO 31. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel) for children being treated with MTX (oral or subcutaneous)?	145–150
Decreasing the MTX dosage or withholding MTX is conditionally recommended if a clinically relevant elevation in LFT results or decreased neutrophil or platelet count is found.	Very low	PICO 32. After MTX (oral or subcutaneous) is initiated, is there a recommended medication change in response to elevated LFT results and decreased neutrophil or platelet count?	150–153
Use of folic/folinic acid in conjunction with MTX is strongly recommended.	Very low	PICO 7. In children with oligoarticular JIA, should dietary or herbal interventions be recommended, in addition to whatever other therapeutic options are used, versus not recommending them?	60
SSZ: Monitoring via CBC counts, LFTs, and renal function tests within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.	Very low	PICO 33. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel) for children with JIA being treated with SSZ?	153–155
Decreasing the SSZ dosage or withholding SSZ is conditionally recommended if a clinically relevant elevation in LFT results or decreased neutrophil or platelet count is found.	Very low	PICO 34. After SSZ is initiated, is there a recommended medication change in response to elevated LFT results and decreased neutrophil or platelet count?	155–157
LEF: Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.	Very low	PICO 35. Should children with JIA receiving LEF have serum creatinine testing, urinalysis, CBC count, and LFTs before and during treatment, per manufacturer's recommendations?	157–158
Altering LEF administration is conditionally recommended if a clinically relevant elevation in LFT results occurs (temporary withholding of LEF if the ALT level is >3 times the upper limit of normal [ULN]), as per the package insert.	Very low	PICO 36. After LEF is initiated, should medication dosage be altered according to the package insert in response to elevated LFT results?	158–159
Baseline and annual retinal screening after starting HCQ are conditionally recommended.	Very low	PICO 37. Should children with JIA receiving treatment with HCQ have annual screening tests with automated visual fields, if age appropriate, plus spectral-domain optical coherence tomography, versus starting annual screening 5 years after treatment initiation?	159
HCQ: Monitoring via CBC counts and LFTs annually is conditionally recommended.	Very low	PICO 38. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel) for children with JIA being treated with HCQ?	159
TNFi: Monitoring via CBC counts and LFTs annually is conditionally recommended.	Very low	PICO 39. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel, and urinalysis) for children with JIA receiving TNFi treatment?	160–161
Abatacept: Doing no routine laboratory monitoring is conditionally recommended.	Very low	PICO 40. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel, and urinalysis) for children with JIA receiving abatacept treatment?	161–162
Tocilizumab: Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.	Very low	PICO 41. Should children with JIA receiving tocilizumab have serum creatinine testing, urinalysis, CBC count, and LFTs before and during treatment, per manufacturer's recommendations?	162
Monitoring of lipid levels every 6 months is conditionally recommended, as per the package insert.			

(Continued)

Table 4. (Cont'd)

Recommendation	Certainty of evidence	PICO evidence report(s) basis	Page no(s). of evidence tables†
Altering tocilizumab administration is conditionally recommended if monitoring reveals elevated LFT results (if 1–3 times the ULN, decrease the dosage or increase the interval between doses, if >3 times the ULN, withhold administration, if >5 times the ULN, discontinue treatment), neutropenia (500–1,000/mm ³), or thrombocytopenia (50,000–100,000/mm ³), as per the package insert.	Very low	PICO 42. After tocilizumab is initiated, should medication dosage be altered according to the package insert in response to elevated LFT results, neutropenia, and/or thrombocytopenia?	163
Anakinra: Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.	Very low	PICO 43. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel, and urinalysis) for children with JIA receiving anakinra treatment?	163–164
Canakinumab: Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.	Very low	PICO 44. Is there a recommended laboratory screening schedule (CBC count, comprehensive metabolic panel, and urinalysis) for children with JIA receiving canakinumab treatment?	164
Tofacitinib: Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.	‡	‡	‡
Monitoring of lipid levels 1–2 months after starting treatment is conditionally recommended, as per the package insert.			
Altering tofacitinib administration is strongly recommended if monitoring reveals laboratory abnormalities of concern. Specifically, medication should be discontinued if the hemoglobin level is <8 gm/dl or decreases by >2 gm/dl, or for severe neutropenia (<500/mm ³) or lymphopenia (<500/mm ³), as per the package insert.			

* PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; CBC = complete blood cell; LFTs = liver function tests; MTX = methotrexate; JIA = juvenile idiopathic arthritis; SSZ = sulfasalazine; LEF = leflunomide; ALT = alanine aminotransferase; ULN = upper limit of normal; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor.

† In Supplementary Appendix 3, on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>.

‡ Given recent approval for JIA and limited experience, recommendations are based on clinical trial, US Food and Drug Administration guidance, and evidence in adults.

(11,12). Therefore, it is worthwhile to address the importance of an age-appropriate diet (13). However, there is no evidence to date that supports the use of a specific diet alone to treat JIA (14,15). Furthermore, some overly restrictive diets (e.g., gluten-free, dairy-free) may result in nutritional deficits and risk of other harms (e.g., delay in treatment, cost, inconvenience).

Supplements

Use of supplemental or herbal interventions specifically to treat JIA is conditionally recommended against.

Voting panelists had concerns about the safety of unregulated supplements and herbal formulations and stressed the importance of discussion and transparency regarding their use. Some evidence of efficacy supports the use of supplements (e.g., fish oils) to treat joint inflammation in adults, but there are only very limited efficacy and safety data for JIA (16).

Monitoring

Medications (Tables 4 and 5)

When making decisions regarding laboratory monitoring to detect medication toxicity, the risk of adverse events and patients'/caregivers' desire for safety should be balanced with the pain, inconvenience, and cost of phlebotomy and laboratory tests. The following recommendations pertain to specific medications or medication classes. If a child is receiving >1 medication, the more frequent schedule for laboratory testing is recommended. In formulating the recommendations below, the Voting Panel considered the US Food and Drug Administration (FDA) prescription drug labels (package inserts) in addition to the studies included in the systematic review.

For medications that are known teratogens (e.g., methotrexate, leflunomide), when applicable, pregnancy testing should be considered before usage, and counseling on effective methods of contraception is recommended (17). When required by the

Table 5. Medication monitoring*

	MTX†‡	SSZ†	LEF‡	Tocilizumab	Anakinra	Tofacitinib	Canakinumab	NSAIDs†	HCQ	TNFi	Abatacept
CBC/diff. count and LFTs											
Baseline											
1–2 months after starting	X	X	X	X	X	X	X	-	-	-	-
Every 3–4 months thereafter§											
CBC/diff. count and LFTs											
Baseline											
Every 6–12 months	-	-	-	-	-	-	-	X	-	-	-
CBC/diff. count and LFTs											
Baseline											
Once yearly	-	-	-	-	-	-	-	-	X	X	-
Lipid panel											
Baseline											
Every 6 months	-	-	-	X	-	-	-	-	-	-	-
Lipid panel											
Baseline											
4–8 weeks after starting	-	-	-	-	-	X	-	-	-	-	-
Eye examination											
Baseline											
Once yearly	-	-	-	-	-	-	-	-	X	-	-
None required											
	-	-	-	-	-	-	-	-	-	-	X

* If the patient is receiving >1 medication, a more restrictive schedule should be used. MTX = methotrexate; SSZ = sulfasalazine; LEF = leflunomide; NSAIDs = nonsteroidal antiinflammatory drugs; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor; CBC/diff. = complete blood cell with differential; LFTs = liver function tests.

† Include renal function testing with laboratory studies.

‡ Pregnancy testing should be considered before use, and counseling on use of effective methods of contraception is recommended.

§ Should be rechecked sooner if dosage is increased.

FDA, a Risk Evaluation and Mitigation Strategy should be applied (18).

Baseline laboratory testing is conditionally recommended prior to treatment initiation, for all medications.

Baseline laboratory evaluation is recommended to identify potential contraindications to a specific treatment. This should include complete blood cell count (CBC) with differential cell count and liver function tests (LFTs) (e.g., alanine aminotransferase [ALT] and aspartate aminotransferase), plus renal function tests (e.g., blood urea nitrogen, creatinine, and urinalysis) for patients being treated with methotrexate, sulfasalazine, or nonsteroidal anti-inflammatory drugs (NSAIDs) and lipid profiles for patients being treated with tocilizumab and tofacitinib. Additional laboratory testing may be performed at the discretion of the treating clinician.

NSAIDs (all)

Monitoring via CBC counts, LFTs, and renal function tests every 6–12 months is conditionally recommended.

NSAIDs are known to be associated with gastrointestinal (GI) bleed risk and liver and kidney toxicity in adults with rheumatic diseases. Although these may be rare in children, the Voting Panel deemed it important to monitor for laboratory abnormalities periodically in children receiving long-term NSAIDs. Because GI

distress when consistently taking NSAIDs is common, patients/caregivers strongly suggested that clinicians should inquire about and potentially treat GI symptoms, which may not always be spontaneously reported (19,20).

Methotrexate

Monitoring via CBC counts, LFTs, and renal function tests within the first 1–2 months of usage and every 3–4 months thereafter is strongly recommended.

Voting panelists debated whether frequent methotrexate toxicity monitoring (as per the package instructions, i.e., CBC count monthly and renal/liver function every 1–2 months) should be recommended for children, given the low incidence of liver toxicity (21,22). However, rare potential for serious harm in children and consistency in monitoring schedule during pediatric-to-adult care transition influenced the panel’s decision to provide a strong recommendation for frequent monitoring (23).

Decreasing the methotrexate dosage or withholding methotrexate is conditionally recommended if a clinically relevant elevation in LFT results or decreased neutrophil or platelet count is found.

The panel did not reach consensus on specific values to define elevated LFT results or reduced cell counts. Clinically

relevant laboratory abnormalities may include repetitive minor abnormalities or a single major abnormality. LFT results may be transiently elevated if testing is done within 2 days after administration of methotrexate; hence, testing within this window is discouraged.

Use of folic/folinic acid in conjunction with methotrexate is strongly recommended.

Use of folic/folinic acid with methotrexate may mitigate adverse events and improve tolerability (24,25).

Sulfasalazine

Monitoring via CBC counts, LFTs, and renal function tests within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.

Recommended monitoring is less frequent than suggested in the package insert for sulfasalazine (which suggests CBC counts and LFTs every second week in the first 3 months, monthly during the next 3 months, and then every 3 months) because most children have fewer comorbidities and polypharmacy usage is rare, allowing for fewer drug interactions (26–28).

Decreasing the sulfasalazine dosage or withholding sulfasalazine is conditionally recommended if a clinically relevant elevation in LFT results or decreased neutrophil or platelet count is found.

While adverse reactions can be serious, including Stevens-Johnson syndrome or drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) (29), the Voting Panel thought the data were too limited to make this recommendation strong.

Leflunomide

Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.

Recommended LFT monitoring is less frequent than suggested in the leflunomide package insert (which recommends CBC counts and ALT testing monthly for 6 months and then every 6–8 weeks) (30) because most children have fewer comorbidities and polypharmacy usage is rare, allowing for fewer drug interactions (31).

Altering leflunomide administration is conditionally recommended if a clinically relevant elevation in LFT results occurs (temporary withholding of leflunomide if the ALT level is >3 times the upper limit of normal [ULN]), as per the package insert.

Elimination of leflunomide can be accelerated with the use of cholestyramine or activated charcoal (30), when required.

Hydroxychloroquine

Monitoring via CBC counts and LFTs annually is conditionally recommended.

As per the hydroxychloroquine package insert (32), periodic laboratory monitoring should be performed if patients are receiving prolonged therapy.

Baseline and annual retinal screening after starting hydroxychloroquine are conditionally recommended.

Yearly screening should be performed in pediatric patients, rather than waiting 5 years between baseline and subsequent annual screening as recommended for hydroxychloroquine-treated adults (33). The cumulative and developmental effects of hydroxychloroquine are a concern because children may be receiving treatment for prolonged periods and may not be able to articulate vision concerns. Baseline retinal screening should be completed as soon as possible and combined with screening for uveitis when feasible. Treatment does not need to be delayed for initial retinal screening.

Tumor necrosis factor inhibitors (TNFi) (all)

Monitoring via CBC counts and LFTs annually is conditionally recommended.

As per package inserts, cytopenias and abnormal LFTs have been reported in association with TNFi treatment. Therefore, evaluation yearly at minimum is recommended (34,35).

Abatacept

Doing no routine laboratory monitoring is conditionally recommended.

In placebo-controlled clinical trials of abatacept for JIA, children had similar CBC counts and LFT results irrespective of treatment arm (36), and no laboratory monitoring is suggested in the package insert (37). The decision to perform laboratory monitoring may be discussed with patients/caregivers who, like some of the voting panelists, may prefer routine monitoring to identify potential adverse events, even if rare.

Tocilizumab

Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.

Monitoring of lipid levels every 6 months is conditionally recommended, as per the package insert.

Altering tocilizumab administration is conditionally recommended if monitoring reveals elevated LFT results (if 1–3 times the ULN, decrease the dosage or increase the interval between doses, if >3 times the ULN, withhold administration, if >5 times the ULN, discontinue treatment), neutropenia (500–1,000/mm³), or thrombocytopenia (50,000–100,000/mm³), as per the package insert.

As per the package insert, initiation of tocilizumab treatment is not recommended in patients with elevated LFT results (>1.5 times the ULN) (38). In patients in whom LFT results become highly elevated (>5 times the ULN), treatment should be discontinued. The package insert does state that the decision to discontinue tocilizumab due to a laboratory abnormality should be based on the medical assessment of the individual patient. For that reason, this recommendation is conditional.

Anakinra

Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.

Abnormal LFTs and neutropenia may occur with the use of anakinra (39). For that reason, as well as the severity of the underlying disease, regular monitoring should be performed.

Canakinumab

Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.

Abnormal LFT results and cytopenias were noted during a phase III clinical trial of canakinumab for systemic JIA (40). For that reason, as well as the severity of the underlying disease, regular monitoring should be performed.

Tofacitinib

Monitoring via CBC counts and LFTs within the first 1–2 months of usage and every 3–4 months thereafter is conditionally recommended.

Monitoring of lipid levels 1–2 months after starting treatment is conditionally recommended, as per the package insert.

Altering tofacitinib administration is strongly recommended if monitoring reveals laboratory abnormalities of concern. Specifically, medication should be discontinued if the hemoglobin level is <8 gm/dl or decreases by >2 gm/dl,

or for severe neutropenia (<500/mm³) or lymphopenia (<500/mm³), as per the package insert.

Data on tofacitinib were not part of the initial literature review, but the panel considered it important to include this recommendation because in 2020 tofacitinib was approved by the FDA for treatment of JIA (41). An additional Voting Panel session was organized for this purpose.

Infection surveillance (Table 6)

Tuberculosis (TB)

TB screening is conditionally recommended prior to starting biologic disease-modifying antirheumatic drug (DMARD) therapy and when there is a concern for TB exposure thereafter.

Concern for TB exposure should be interpreted broadly and could include contact with someone with active TB, travel to locations where TB is endemic, contact with high-risk individuals (e.g., prisoners, visitors from TB-endemic areas), or living in communities with a higher frequency of TB (42,43). The conditional recommendation reflects 2 major concerns: In certain urgent clinical situations, the harms of waiting for results of TB screening may outweigh the benefits of treatment. For example, in a child with active systemic JIA and macrophage activation syndrome (MAS), treatment should not be delayed pending TB screening results. Annual screening for TB can pose problems for children and families. Insurers or institutions may require a specific method that is potentially problematic (44,45). For example, TB screening may be done by questionnaire; however, this depends on knowledge of exposure. The interferon- γ release assay is expensive, not valid in young children, and subject to frequent indeterminate results, particularly during anergy. Tuberculin skin testing is user dependent and inconvenient because 2 visits are required. In addition, false-positive results often lead to unnecessary chest radiography and isoniazid treatment. For children living in areas with a low prevalence of TB, mandatory annual laboratory-based TB screening represents a high burden of cost, inconvenience, and pain that is not supported by the literature reviewed.

Viral infections

Voting panelists could not reach consensus on whether all children with JIA should have antibody titers for specific infections (e.g., measles, varicella, hepatitis B, hepatitis C) checked prior to starting immunosuppressive medication, although more panelists were against this practice than for it. Some panelists believed the information might be useful for risk management in case of an outbreak or exposure. Most believed that screening a fully immunized child was of low benefit and might delay treatment and incur unnecessary cost. Although

Table 6. Infection surveillance/immunizations*

Recommendation	Certainty of evidence	PICO evidence report(s) basis	Page no(s). of evidence table†
No consensus achieved.	Very low	PICO 45. Should all children with JIA have infection titers (measles, varicella, hepatitis B, hepatitis C) checked prior to starting immunosuppressive medication?	164–166
Immunization is conditionally recommended for children with active non-systemic JIA who have not yet been immunized for measles, mumps, rubella, and/or varicella prior to starting immunosuppressive medications.	Very low	PICO 46. Should children with JIA with no evidence of immunity to important infections have a booster immunization prior to starting immunosuppressive medication?	166
TB screening is conditionally recommended prior to starting biologic DMARD therapy and when there is a concern for TB exposure thereafter.	Very low	PICO 47. Should screening for TB be done prior to starting biologic DMARD therapy and then annually in children with JIA?	167–169
	Very low	PICO 48. In children with JIA receiving biologic DMARD therapy, is there a preferred method of TB screening?	169–171
Immunizations (live and inactivated) are strongly recommended for children with JIA who are not receiving immunosuppressive treatment.	Very low	PICO 49. In children with JIA not receiving immunosuppressive treatment, do inactivated or live attenuated vaccines result in flare of disease?	172–175
Annual inactivated influenza immunization is strongly recommended for all children with JIA.	Low	PICO 50. In children with JIA not receiving immunosuppressive treatment, are patients able to develop protective antibodies against infections targeted by the vaccine?	175–179
		PICO 52. In children with JIA receiving immunosuppressive treatment, are patients able to develop protective antibodies against infections targeted by the vaccine?	184–195
Inactivated vaccines are strongly recommended for children who are receiving immunosuppressive treatment.	Very low	PICO 51. In children with JIA receiving immunosuppressive treatment, do inactivated vaccines result in flare of disease?	180–184
Live attenuated vaccines are conditionally recommended <i>against</i> in children with JIA who are receiving immunosuppressive treatment.	Low	PICO 53. In children with JIA receiving immunosuppressive treatment, can treatment with live attenuated vaccines be given safely (initial dose, booster dose)?	195–198
Vaccines are strongly recommended for household contacts of children with JIA who are receiving immunosuppressive treatment.	Very low	PICO 54. Can live attenuated vaccines be used safely in the households of children with JIA receiving immunosuppressive treatment?	198

* PICO = Patient/Population, Intervention, Comparison, and Outcomes; JIA = juvenile idiopathic arthritis; TB = tuberculosis; DMARD = disease-modifying antirheumatic drug.

† In Supplementary Appendix 3, on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>.

screening for hepatitis B and C is done in adults prior to treatment with DMARDs, most children are effectively immunized against hepatitis B as infants (46), and the number of children below the age of 19 years with hepatitis C in the US remains exceedingly low (47).

Immunizations (Table 6)

Because some patients/caregivers have concerns about the safety of vaccines in JIA, clinicians must discuss with families the evidence that strongly supports their benefits and safety. Whenever possible, immunizations should be administered according to the schedule recommended by the ACIP and the AAP or corresponding national recommendations. As immunization schedules are frequently updated, clinicians should ensure that they are using the

most recent versions (48). Multiple cohort studies have demonstrated that most children with JIA mount a protective response after immunizations and that immunizations do not cause disease flare (49–52).

Annual inactivated influenza immunization is strongly recommended for all children with JIA

All children with JIA, including children receiving immunosuppressive medication, should receive inactivated influenza immunizations annually (53). This recommendation is strong despite very low evidence in JIA, given the overwhelming preponderance of supporting literature in other inflammatory diseases and the risk of severe infection (54–57). Intranasal influenza immunization is contraindicated for children with JIA who are receiving immunosuppressive treatment, as it is a live attenuated immunization.

Table 7. Imaging*

Recommendation	Certainty of evidence	PICO evidence report(s) basis	Page no(s) of evidence tables†
Use of radiography as a screening test prior to advanced imaging, for the purpose of identifying active synovitis or enthesitis, is strongly recommended against .	Very low	PICO 55. In children with JIA, is any specific imaging technique recommended to best detect inflammation and damage, make a diagnosis, and predict structural damage, flare, or treatment response?	199–268
Imaging guidance is conditionally recommended for use with intraarticular glucocorticoid injections of joints that are difficult to access, or to specifically localize the distribution of inflammation.	Very low	PICO 56. In children with JIA who require intraarticular glucocorticoid injections, should injections be done with imaging guidance?	269–279

* PICO = Patient/Population, Intervention, Comparison, and Outcomes; JIA = juvenile idiopathic arthritis.

† In Supplementary Appendix 3, on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>.

Immunizations (live attenuated and inactivated) are strongly recommended for children with JIA who are not receiving immunosuppressive treatment

Children with JIA have a higher risk of severe infection compared to unaffected children, making adequate protections against infection essential (58). Considerations of the relative degree of immunosuppression from various immunosuppressive medications used for JIA is beyond the scope of this project. To err on the side of safety, these recommendations apply equally to any child receiving an immunosuppressive medication for JIA (e.g., DMARDs, long-term systemic glucocorticoids) (59).

Inactivated vaccines are strongly recommended for children with JIA who are receiving immunosuppressive treatment.

Persons with JIA should receive inactivated vaccines as per location-specific, published age-related schedule. Specifically, children undergoing immunosuppressive treatment should receive the 23-valent pneumococcal polysaccharide vaccine in addition to the 13-valent pneumococcal conjugate vaccine recommended for all children (60,61).

Live attenuated vaccines are conditionally recommended against in children with JIA who are receiving immunosuppressive treatment.

As reported by the US Centers for Disease Control and Prevention (CDC), severe complications have followed vaccination with certain live attenuated viral and bacterial vaccines among immunosuppressed persons (62). Therefore, guidelines recommend that persons with most forms of altered immunocompetence should not receive live attenuated vaccines. According to the CDC, live-virus vaccination should be deferred for 1–6 months after discontinuation of immunosuppressive treatment, depending on the specific agent (62). There is some evidence that booster immunization with live attenuated vaccines may be safe for children with JIA who are receiving certain specific immunosuppressants (52,63). More work is needed to support a formal recommendation in this setting, as studies thus far have been underpowered to detect rare, serious harms.

Immunization is conditionally recommended for children with active non-systemic JIA who have not yet been immunized for measles, mumps, rubella, and/or varicella prior to starting immunosuppressive medications.

This recommendation excludes active, untreated systemic JIA in which delaying treatment initiation for vaccinations may be prohibitive. As per the CDC, immunosuppressive therapy should not be initiated until 4 weeks after administration of a live vaccine and ideally 2 weeks after administration of an inactivated vaccine. If withholding/delaying medication is not feasible, live-attenuated vaccine immunization should be deferred and given at a later time when disease is in remission and the child is no longer being treated (64).

Vaccines are strongly recommended for household contacts of children with JIA who are receiving immunosuppressive treatment.

Immunization of household members of immunosuppressed children is critical to diminish exposure in the home. Household contacts and other close contacts of persons with altered immunocompetence should receive all age- and exposure-appropriate vaccines, whether inactivated or live, with the exception of smallpox vaccine (59,65). If a family member has received varicella vaccine and develops a rash, direct contact should be avoided until the rash resolves. Likewise, all members of the household should wash their hands after changing the diaper of an infant who recently received rotavirus vaccine, to minimize transmission. If concerns remain, CDC or local guidelines can be reviewed prior to immunization.

Imaging (Table 7)

Use of radiography as a screening test prior to advanced imaging, for the purpose of identifying active synovitis or enthesitis, is strongly recommended against.

Radiography is not sensitive enough to assess joint inflammation and enthesitis in children and may delay clinically appropriate imaging and treatment (66–68). Unnecessary radiation can result in significant harm to developing children (69). Conventional

radiography should be restricted to the assessment of JIA-associated damage or to investigate alternative diagnoses.

Imaging guidance is conditionally recommended for use with intraarticular glucocorticoid injections of joints that are difficult to access, or to specifically localize the distribution of inflammation.

This recommendation includes ultrasound and/or fluoroscopy. Specific joints that may be difficult to access include sacroiliac joints, hips, TMJs, shoulder, midfoot, and subtalar joints. This recommendation is conditional because it is dependent on the skill of the practitioner, availability of imaging, costs, and risk of delay in treatment (70–72).

DISCUSSION

The recommendations presented in this guideline are a companion to those published in 2019 (3,4) and concurrently (73) and cover areas not previously addressed in JIA: nonpharmacologic treatments, medication monitoring, immunization, and imaging. Similar to recommendations made for oligoarthritis, TMJ arthritis, and systemic JIA with and without MAS, one must view this guideline as a road map for future study (Supplementary Appendix 7, available on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42036/abstract>). Most of the available evidence was very low quality for the relevant PICO questions, contributing to 23 of the 33 recommendations being conditional. None of the recommendations were supported by moderate- or high-quality evidence.

Nowhere is the discrepancy between patient/caregiver interest and available data more evident than in the consideration of nonpharmacologic therapies, for which recommendations were included at patient/parent request. Use of specific diets and supplements was discussed extensively by the patient/caregiver panel, including sharing of suggested regimens and reference materials. There was a general belief that disease manifestations could be ameliorated by changes in foods consumed and great interest in participating in formal research studies on nutritional interventions. Most panelists recognized the importance of PT/OT, and inclusion of PT and OT specialists on the Voting Panel would allow for more specific recommendations in future guidelines.

Likewise, patients and caregivers discussed the stress of dealing with chronic illness and the need for mental health interventions. As recently as 2017, when the scope of this project was established, mental health care for children and families affected by rheumatic diseases was not a major focus. For this reason, although mental health was recognized by the Voting Panel as important, it was not formally addressed in this guideline. Future guidelines should include recommendations addressing mental health screening and treatments, with input from mental health professionals on the Voting Panel. This is particularly

important given the impact of the COVID-19 pandemic on the mental health of persons with chronic disease (74).

Medication monitoring remains especially challenging in JIA, and balancing safety, cost, pain, and inconvenience can be very difficult. Some panel members asserted that monitoring was perhaps less important in a generally healthy pediatric population relative to adults with comorbidities. Due to the low frequency of serious comorbidities and interacting medications, and limited-to-no exposure to alcohol and other toxins, laboratory abnormalities requiring medication discontinuation are rare in children with JIA. However, other panel members believed strongly that monitoring needs to be routinely performed to identify rare but serious adverse events. Recommendations as written attempted to balance these concerns. Future research and guidelines should consider altered, less frequent monitoring schedules for younger children, given the potentially lower risks of toxicity and greater risks of frequent testing at the youngest ages.

The list of available immunosuppressive medications for JIA for which monitoring is required has grown substantially and will continue to expand. Two new agents were recently approved for use in polyarticular-course JIA: golimumab (a TNFi) and tofacitinib (a JAK inhibitor) (41,75). With regard to laboratory testing to detect abnormalities in monitoring for toxicity, voting panelists could not agree on a single definition of “clinically relevant” abnormal results and left this to the discretion of treating clinicians. Caregivers and patients expressed the challenges of balancing the need to ensure medication safety with the cost and inconvenience associated with blood withdrawal. It is hoped that in the future, effective, reliable treatments that require less monitoring will be available for JIA.

Voting panelists did believe strongly that age must be taken into consideration in requirements for infection screening in the US prior to initiation of treatment with DMARDs. TB, hepatitis B, and hepatitis C are extremely rare in fully immunized nonimmigrant children in the US, and annual TB screening presents a large and unnecessary burden. There were engaged discussions about screening for viral infections prior to the use of DMARDs; however, most thought that lack of immunity in a child known to be immunized was likely to be rare. Even if antibody titers were low or absent after vaccination, cell-mediated immunity was considered likely to be present.

In light of the COVID-19 pandemic, discussion of immunizations in these guidelines proved to be extremely timely. Despite the potential severity of vaccine-preventable infections in immunosuppressed populations, vaccine hesitancy remains common. Nonetheless, preventing infectious illnesses in an immunosuppressed patient population is critical. Many families have concerns regarding vaccine safety, immunogenicity, risk of flare, and other potential long-term consequences. Studies in JIA have consistently demonstrated the safety and effectiveness of vaccines to induce protective immune responses. Regarding immunization for COVID-19, available immunizations vary by

age, accessibility, and country. There are currently no preferences for a specific vaccine in a given population of children with rheumatic disease. Physicians should refer to local recommendations. At the time this manuscript was approved for publication, the Pfizer-BioNTech COVID-19 vaccine was approved in the US for adolescents age ≥ 16 years (76) and authorized for emergency use in children 5–15 years of age (77,78). No vaccines for COVID-19 were yet available for younger children, although studies are ongoing. As none of the currently available vaccines against COVID-19 are live vaccines, recommendations should be similar to those stated above for inactivated vaccines. While specific guidance on immunizing children with rheumatic diseases against COVID-19 is still lacking, the ACR has published guidance on COVID-19 vaccines for adults with rheumatic and musculoskeletal diseases (79). Patients and family members have articulated the importance of health care providers for reliable medical information. We must be mindful that clinicians are trusted sources of information about this important public health issue and should discuss immunizations with their patients.

With regard to imaging, it is clear that different modalities are appropriate for different indications. Radiographs are not useful for evaluation of soft tissue disease, and continued third-party payor requirements for radiographs prior to any and all magnetic resonance imaging (MRI) are a waste of resources and a potential hazard to persons with JIA. MRI itself may require sedation, and there is concern that repeated sedation in young children may carry risks (80). More research is needed to define and standardize the best approaches to imaging in children with JIA for different diagnostic and disease management decision-making purposes.

Addressing each area of the JIA guidelines at the same time proved to be a Herculean task. This update of the ACR JIA guidelines has taken 4 years to complete, leading to 4 manuscripts; certain areas are already ready for further updates. Health care around the world is quickly changing in unforeseen ways, and rheumatologists have been thrust into the forefront of recent pandemic developments in an unparalleled manner (81). The pace of change will likely only increase, and guidelines will need to be updated nimbly and more frequently over time.

The low quality of evidence supporting most of the recommendations underscores the importance of clinical judgment and shared decision-making in everyday care of patients with JIA. Similarly, these guidelines and the many uncertainties therein represent a powerful reminder of the need for more high-quality evidence to support (or refute) current practices and to improve disease management in—and well-being of—all individuals living with JIA.

In conclusion, this 2021 updated ACR guideline for JIA recommends the use of PT and OT interventions; a healthy, well-balanced, age-appropriate diet; specific laboratory monitoring for different antirheumatic medications; widespread use of

immunizations; and need for shared decision-making with patients/caregivers. The JIA guidelines will continue to be updated as new evidence emerges.

ACKNOWLEDGMENTS

We thank Jennifer Horonjeff who (along with author Katherine Murphy) participated in the Patient Panel meeting. We thank the ACR staff, including Regina Parker for assistance in coordinating the administrative aspects of the project and Cindy Force for assistance with manuscript preparation. We thank Janet Waters for assistance in developing the literature search strategy as well as performing the initial literature search and update searches.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Onel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Onel, Horton, Lovell, Shenoi, Cuello, Lee, Murphy, Barbar-Smilely, Edelheit, Sullivan, Turner.

Acquisition of data. Onel, Horton, Lovell, Shenoi, Kimura, Lee, Murphy, Nigrovic, Ombrello, Rabinovich, Twilt, Barbar-Smilely, Cooper, Edelheit, Gillispie-Taylor, Hays, Mannion, Peterson, Flanagan, Saad, Sullivan, Szymanski, Trachtman, Reston.

Analysis and interpretation of data. Onel, Horton, Lovell, Shenoi, Cuello, Angeles-Han, Becker, Cron, Feldman, Ferguson, Gewanter, Guzman, Kimura, Nigrovic, Ombrello, Rabinovich, Teshler, Twilt, Kleingitman, Cooper, Edelheit, Gillispie-Taylor, Mannion, Sullivan, Szymanski, Trachtman, Turgunbaev, Veiga, Reston.

REFERENCES

1. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res (Hoboken)* 2011;63:465–82.
2. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum* 2013;65:2499–512.
3. Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol* 2019;71:846–63.
4. Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. *Arthritis Rheumatol* 2019;71:864–77.
5. Onel KB, Shenoi S. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis (JIA): therapeutic approaches for oligoarthritis, temporomandibular joint arthritis (TMJ), and systemic JIA, medication monitoring, immunizations and

- non-pharmacologic therapies. Presented at ACR Convergence; 2020 November 3–10; Atlanta, Georgia.
6. Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines. 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. *J Clin Epidemiol* 2013;66:726–35.
 7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
 8. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *CMAJ* 2010;182:E839–42.
 9. Kuntze G, Nesbitt C, Whittaker JL, Nettel-Aguirre A, Toomey C, Esau S, et al. Exercise therapy in juvenile idiopathic arthritis: a systematic review and meta-analysis. *Arch Phys Med Rehabil* 2018;99:178–93.
 10. Tarakci E, Arman N, Tarakci D, Kasapcopur O. Leap Motion Controller-based training for upper extremity rehabilitation in children and adolescents with physical disabilities: a randomized controlled trial. *J Hand Ther* 2020;33:220–8.
 11. Das JK, Salam RA, Thornburg KL, Prentice AM, Campisi S, Lassi ZS, et al. Nutrition in adolescents: physiology, metabolism, and nutritional needs. *Ann N Y Acad Sci* 2017;1393:21–33.
 12. Beluska-Turkan K, Korczak R, Hartell B, Moskal K, Maukonen J, Alexander DE, et al. Nutritional gaps and supplementation in the first 1000 days [review]. *Nutrients* 2019;11:2891.
 13. Gidding SS, Dennison BA, Birch LL, Daniels SR, Gillman MW, Lichtenstein AH, et al. Dietary recommendations for children and adolescents: a guide for practitioners. *Pediatrics* 2006;117:544–59.
 14. Schrandt JJ, Marcelis C, de Vries MP, van Santen-Hoeufft HM. Does food intolerance play a role in juvenile chronic arthritis? *Br J Rheumatol* 1997;36:905–8.
 15. Nousiainen P, Merras-Salmio L, Aalto K, Kolho KL. Complementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis. *BMC Complement Altern Med* 2014;14:124.
 16. Gheita T, Kamel S, Helmy N, El-Laithy N, Monir A. Omega-3 fatty acids in juvenile idiopathic arthritis: effect on cytokines (IL-1 and TNF- α), disease activity and response criteria. *Clin Rheumatol* 2012;31:363–6.
 17. Drechsel P, Studemann K, Niewerth M, Horneff G, Fischer-Betz R, Seipelt E, et al. Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis: results from a JIA biologic registry. *Rheumatology (Oxford)* 2020;59:603–12.
 18. Meyer BM. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications. *Am J Health Syst Pharm* 2009;66 Suppl:S3–5.
 19. Vora SS, Bengtson CE, Syverson GD, Nocton JJ. An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review. *Pediatr Rheumatol Online J* 2010;8:11.
 20. Blecker U, Gold BD. Gastritis and peptic ulcer disease in childhood. *Eur J Pediatr* 1999;158:541–6.
 21. Franova J, Fingerhutova S, Kobrova K, Srp R, Nemcova D, Hoza J, et al. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. *Pediatr Rheumatol Online J* 2016;14:36.
 22. Kocharla L, Taylor J, Weiler T, Ting TV, Luggen M, Brunner HI. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. *J Rheumatol* 2009;36:2813–8.
 23. Singh JA, Saag KG, Bridges SL Jr, Aki EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol* 2016;68:1–26.
 24. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis: a controlled study. *J Rheumatol* 1997;24:2230–2.
 25. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 1999;17:625–7.
 26. Sulfasalazine. New York: Pfizer; 2021. URL: <http://labeling.pfizer.com/ShowLabeling.aspx?id=524>
 27. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. *J Rheumatol* 1996;23:360–6.
 28. Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al, on behalf of the Dutch Juvenile Chronic Arthritis Study Group. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. *Arthritis Rheum* 1998;41:808–16.
 29. Tremblay L, de Chambrun GP, De Vroey B, Lavogiez C, Delaporte E, Colombel JF, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. *J Crohns Colitis* 2011;5:457–60.
 30. Leflunomide prescribing information. Bridgewater (NJ): Sanofi; 2021. URL: <https://products.sanofi.us/arava/arava.pdf>.
 31. Baker C, Feinstein JA, Ma X, Bolen S, Dawson NV, Golchin N, et al. Variation of the prevalence of pediatric polypharmacy: a scoping review. *Pharmacoepidemiol Drug Saf* 2019;28:275–87.
 32. Hydroxychloroquine. Bridgetown (Barbados): Concordia Pharmaceuticals; 2015. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s0471bl.pdf.
 33. Wei Q, Wang W, Dong Y, Zhong L, Song H. Five years follow-up of juvenile lupus nephritis: a single-center retrospective cohort study. *Ann Palliat Med* 2021;10:7351–9.
 34. Azevedo VF, Silva MB, Marinello DK, Santos FD, Silva GB. Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review. *Rev Bras Reumatol* 2012;52:110–2.
 35. Adalimumab prescribing information. North Chicago: AbbVie; 2021. URL: <https://www.rxabbvie.com/pdf/humira.pdf>.
 36. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. *Lancet* 2008;372:383–91.
 37. Abatacept prescribing information. Princeton (NJ): Bristol Myers Squibb; 2017. URL: https://packageinserts.bms.com/pi/pi_orencia.pdf.
 38. Tocilizumab prescribing information. San Francisco: Genentech; 2021. URL: https://www.gene.com/download/pdf/actemra_prescribing.pdf.
 39. Diallo A, Mekinian A, Boukari L, Mouas H, Zamy M, Nahon P, et al. Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra. *Rev Med Interne* 2013;34:168–70. In French.
 40. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. *N Engl J Med* 2012;367:2396–406.
 41. Tofacitinib. New York: Pfizer; 2020. URL: <https://labeling.pfizer.com/ShowLabeling.aspx?id=959#section-5.7>.
 42. Tuberculosis (TB): TB and Children. Centers for Disease Control and Prevention. 2021 URL: <https://www.cdc.gov/tb/topic/populations/tbinchildren/default.htm#:~:text=TB%20skin%20testing%20is%20considered,than%205%20years%20of%20age.&text=All%20children%20with%20a%20positive,should%20undergo%20a%20medical%20evaluation>.
 43. Cowger TL, Wortham JM, Burton DC. Epidemiology of tuberculosis among children and adolescents in the USA, 2007–17: an analysis of national surveillance data. *Lancet Public Health* 2019;4:e506–16.
 44. Gaensbauer J, Young J, Harasaki C, Aiona K, Belknap R, Haas MK. Interferon- γ release assay testing in children younger than 2 years in a US-based health system. *Pediatr Infect Dis J* 2020;39:803–7.

45. Boncuoglu E, Kiyimet E, Sahinkaya S, Akaslan Kara A, Caglar I, Arikian KO, et al. Usefulness of screening tests for diagnosis of latent tuberculosis infection in children. *Pediatr Pulmonol* 2021;56:1114–20.
46. Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. *Vaccine* 2001;19:3912–8.
47. Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases—United States, 2009–2018. *MMWR Morb Mortal Wkly Rep* 2020;69:399–404.
48. Robinson CL, Bernstein H, Poehling K, Romero JR, Szilagyi P. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:130–2.
49. Aikawa NE, Trudes G, Campos LM, Pereira RM, Moraes JC, Ribeiro AC, et al. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. *Lupus* 2013;22:1394–8.
50. Toplak N, Subelj V, Kveder T, Cucnik S, Prosenc K, Trampus-Bakija A, et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2012;30:436–44.
51. Heijstek MW, Scherpernisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. *Ann Rheum Dis* 2014;73:1500–7.
52. Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. *JAMA* 2013;309:2449–56.
53. Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2020–21 influenza season. *MMWR Recomm Rep* 2020;69:1–24.
54. Benchimol EI, Hawken S, Kwong JC, Wilson K. Safety and utilization of influenza immunization in children with inflammatory bowel disease. *Pediatrics* 2013;131:e1811–20.
55. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. *J Cutan Med Surg* 2019;23:50–74.
56. Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. *Pediatr Infect Dis J* 2011;30:208–11.
57. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis* 2020;79:39–52.
58. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum* 2012;64:2773–80.
59. Centers for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP: altered immunocompetence. URL: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>.
60. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2012;61:816–9.
61. Strikas RA, Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices, ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years—United States, 2015. *MMWR Morb Mortal Wkly Rep* 2015;64:93–4.
62. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014;58:309–18.
63. Uziel Y, Moshe V, Onozo B, Kulcsar A, Trobert-Sipos D, Akikusa JD, et al. Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. *Vaccine* 2020;38:2198–201.
64. American Academy of Pediatrics. Immunization in special clinical circumstances. In: Pickering LK, Baker CJ, Kimberlin D, Long S, editors. *Red Book: 2009 report of the Committee on Infectious Diseases*. 28th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2009. p. 68–104.
65. Petersen BW, Damon IK, Pertowski CA, Meaney-Delman D, Guarizo JT, Beigi RH, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. *MMWR Recomm Rep* 2015;64:1–26.
66. Oren B, Oren H, Osma E, Cevik N. Juvenile rheumatoid arthritis: cervical spine involvement and MRI in early diagnosis. *Turk J Pediatr* 1996;38:189–94.
67. Malattia C, Damasio MB, Pistorio A, Ioseliani M, Vilca I, Valle M, et al. Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. *Ann Rheum Dis* 2011;70:440–6.
68. Sureda D, Quiroga S, Arnal C, Boronat M, Andreu J, Casas L. Juvenile rheumatoid arthritis of the knee: evaluation with US. *Radiology* 1994;190:403–6.
69. De Gonzalez AB, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. *Lancet* 2004;363:345–51.
70. Young CM, Shiels WE II, Coley BD, Hogan MJ, Murakami JW, Jones K, et al. Ultrasound-guided corticosteroid injection therapy for juvenile idiopathic arthritis: 12-year care experience. *Pediatr Radiol* 2012;42:1481–9.
71. Laurel L, Court-Payen M, Nielsen S, Zak M, Fasth A. Ultrasonography and color Doppler in juvenile idiopathic arthritis: diagnosis and follow-up of ultrasound-guided steroid injection in the wrist region. A descriptive interventional study. *Pediatr Rheumatol Online J* 2012;10:11.
72. Resnick CM, Vakilian PM, Kaban LB, Peacock ZS. Is intra-articular steroid injection to the temporomandibular joint for juvenile idiopathic arthritis more effective and efficient when performed with image guidance? *J Oral Maxillofac Surg* 2017;75:694–700.
73. Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Rheumatol* 2022;74:553–69.
74. Adhne A, Nadiri K, Soussan I, Coulibaly S, Berrada K, Najdi A, et al. Mental health problems experienced by patients with rheumatic diseases during COVID-19 pandemic. *Curr Rheumatol Rev* 2021;17:303–11.
75. Pharmacy Times. FDA approves golimumab for active polyarticular juvenile idiopathic arthritis, extension of PsA indication. 2020. URL: <https://www.pharmacytimes.com/news/fda-approves-golimumab-for-active-polyarticular-juvenile-idiopathic-arthritis-extension-of-psa-indication>.
76. US Food and Drug Administration. News release: FDA approves first COVID-19 vaccine. 2021. URL: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine>.

77. US Food and Drug Administration. News release: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. 2021. URL: <https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age>.
78. US Food and Drug Administration. News release: coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. 2021. URL: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use>.
79. Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3. *Arthritis Rheumatol* 2021;73:e60–70.
80. US Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes for use of general anesthetic and sedation drugs in young children. 2017. URL: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-use-general-anesthetic-and-sedation-drugs>.
81. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. *Arthritis Rheumatol* 2021;73:e13–29.